Conference Coverage (Vancouver AIDS Conference)

Human mAb Protects Against Many HIV Strains

Published in Gene Therapy Weekly, September 9th, 1996

Passive immunization with a single genetically engineered human antibody offered complete protection against a number of HIV strains in an animal model.

The recombinant human monoclonal antibody (mAb) is called IgG1 b12.

"This antibody is being developed for immunoprophylaxis and immunotherapy of HIV-1 infection in humans," said Paul W.H.I. Parren of The Scripps Research Institute, La Jolla, California.

Parren described development and testing of IgG1 b12 at the XI International Conference on AIDS, held July 7-12, 1996, in Vancouver, British Columbia, Canada.

Parren and colleagues began their search for the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry